What Mirum’s Bluejay acquisition reveals about its long-term liver disease strategy
Mirum adds brelovitug in HDV through Bluejay deal. See how this could redefine rare liver disease leadership ahead of AZURE Phase 3 results in 2026.
Pharma & Biotech
Pharma & Biotech
Fortitude Biomedicines enters the degradation race with catalytic ADC platform GLUE-DACTM
Fortitude Biomedicines launches with $13M to develop glue-payload ADCs for autoimmune and cancer treatment. Find out what makes this platform different.
Pharma & Biotech
Can Sarepta’s ELEVIDYS redefine Duchenne therapy? Inside the 3-year EMBARK data
Sarepta’s gene therapy ELEVIDYS shows 3-year durability in Duchenne muscular dystrophy. Find out what it means for patients, payers, and global rollout.
Pharma & Biotech
Nocion Therapeutics reveals new pain data: Is a platform pivot underway?
Find out how Nocion’s nocions™ could change pain treatment by silencing activated neurons without opioids. New preclinical data inside.
Pharma & Biotech
Novaliq targets uveitis with EyeSol-based NOV05: Can topical tacrolimus go intraocular?
Novaliq’s NOV05 enters Phase 2 trials for anterior uveitis. Can it deliver steroid-free, topical relief for inner-eye inflammation? Find out what’s next.
Pharma & Biotech
How United Therapeutics is betting on scaffold-based liver support in high-mortality ALF
United Therapeutics’ miroliverELAP showed positive phase 1 safety results in acute liver failure. Find out what this could mean for future liver support strategies.
Pharma & Biotech
Why Aviva Bio’s deuterated testosterone may change hormone therapy for women
Aviva Bio’s AVA‑291 receives FDA development feedback for women’s testosterone therapy. See what makes it safer and what happens next in clinical trials.
Pharma & Biotech
Genethon advances Duchenne gene therapy trial while licensing Pompe tech to Bayer’s AskBio
Genethon advances gene therapies for Duchenne and Pompe disease. Find out what its nonprofit model and AskBio licensing deal mean for rare disease care.
Pharma & Biotech
Eisai and Biogen advance injectable Alzheimer’s therapy with FDA fast-track decision
FDA fast-tracks Eisai’s LEQEMBI IQLIK for at-home Alzheimer’s care. Find out what this means for patients, payers, and delivery models today.
Pharma & Biotech
Landmark FDA nod gives MSC developers long-awaited quality benchmark for clinical use
The FDA has recognized Tasly’s 3P assay as the first quality control standard for MSCs. Find out what this changes for developers and regulators.